GcMAF helps fight Autism and Cancer by rebuilding body’s immune system.

Guernsey, UK (February 8, 2013) — On February 1, 2013, in simultaneous presentations at the Immunology Conference in San Diego, California and at the International Cancer Conference at the University of Sharjah in the United Arab Emirates, Guernsey-based company, Immuno Biotech Ltd. presented its latest research paper on GcMAF. The presentation was entitled “Multifaceted immunotherapeutic effects of GcMAF on human breast cancer cells.”

It included videos, taken through high powered microscopes in their laboratory, showing cancer cells being destroyed using GcMAF molecules, which they had extracted from human blood. GcMAF is a key part of the human body’s immune system and the body’s own production is often reduced as part of the attacking mechanism of diseases and cancer.

Lynda Thyer presented to an audience of over 200 American scientists at the Immunology Conference and was congratulated on the content by other scientists afterwards, in particular the videos which are a world first.

David Noakes, the CEO of Immuno Biotech, presented at the International Cancer Conference and was told afterwards that his presentation was the most easily understood in the three days of the conference. The University was sufficiently impressed to ask Immuno Biotech to provide GcMAF for use with the University’s huge library of 2,000 cancer cell lines, so that GcMAF can be tested with many more types of cancers in the laboratory. This will extend the knowledge of the effectiveness of GcMAF which has mainly been used in human trials so far. The University of Sharjah is one of the world leaders in cancer and molecular research, with state-of-the-art facilities attracting resident professors from all over the world.

David Noakes will also be presenting Immuno Biotech’s “GcMAF in Autism” research paper at the International Dubai Autism Conference, which was based on a US trial with 1500 autistic children. Most of them had significant reductions in autistic symptoms indicating that infection is playing a role in some forms of autism. The company has already been asked to supply GcMAF for three Dubai autism trials, on top of the 1,500 autistic children already treated. The conference will be held from February 6-9, 2013 at Zayed University, Dubai, bringing together international certified experts in the fields of behavioural therapy and special education.

There are 59 research papers by 142 eminent scientists on GcMAF, and Immuno Biotech Ltd are immensely proud to be adding their first two research papers to the list, with plans for lab experiments and human trial results data for at least another six papers this year.

David Noakes, Immuno Biotech’s CEO, said, “Isolating GcMAF is a complex process. Many scientists find it very challenging and time consuming and often fail to isolate it correctly and so they come to us as a source of consistent quality for their research. We have perfected our process in a state-of-the-art laboratory in the UK that isolates GcMAF from human blood and makes it available in a pure, sterile form to scientists, doctors, patients and researchers around the World. We are continually delighted by the flood of positive results in scientific papers that state GcMAF helps fight an increasingly wide range of diseases.”

The quality of Immuno Biotech’s GcMAF has made it the World’s leading supplier and the provider of choice for scientists with the company being cited in over eight research papers to date. Many of the independent research papers on GcMAF are listed on its website http://www.gcmaf.eu.

Background
GcMAF is continually produced by healthy humans and is a vital part of the body’s immune system. It directs the immune system to destroy foreign invaders, such as viruses and bacteria, as well as the body’s own cells when they turn cancerous. However, many diseases attempt to prevent production of the body’s own GcMAF and, if successful, that prevents the immune system from fighting them resulting in the diseases growing unchecked and becoming chronic.

Immuno Biotech has perfected the technique of extracting and isolating GcMAF molecules from healthy human blood. A weekly injection of a tiny clear drop restores the level of GcMAF in the blood to normal and enables the body’s own natural defence mechanisms to fight the infection with the only occasional side effects being mild, cold-like symptoms as the immune system starts to function normally. Noticeable improvements usually happen within three weeks and the time it takes for the body to fight the infection and return to being able to produce normal levels of its own GcMAF depends on the severity of the infection or cancer. An eight week course costs €660 including shipping so a typical 24 week course costs under €2000 – a fraction of the cost of chemotherapy, and according to the research papers, more effective at fighting cancer. Immuno Biotech has supplied 4,000 patients through 300 doctors in 30 nations.

Immuno Biotech Contact: Beate Keisa, Immuno Biotech Ltd., Tel: 0044 7781 411737, Web: http://gcmaf.eu and click “contact” at the top to email.